Description:

Size: 100ul

Catalog no.: bs-11800R-A488

Price: 380 EUR

Product details

Modification Site

None

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

499nm/519nm

Concentration

1ug per 1ul

Conjugation

Alexa Fluor

Subcellular location

Extracellular

Tested applications

FCM, IF(IHC-P)

Conjugated with

ALEXA FLUOR® 488

Crossreactivity

Human, Mouse, Rat

Clone

Polyclonal antibody

Target Antigen

AVPR1B/AVP Receptor V3

Purification

Purified by Protein A.

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Recommended dilutions

FCM(1:20-100), IF(IHC-P)(1:50-200)

Also known as

Anti-AVPR1B/AVP Receptor V3 PAb ALEXA FLUOR 488

Long name

AVPR1B/AVP Receptor V3 Antibody, ALEXA FLUOR 488 Conjugated

Specificity

This is a highly specific antibody against AVPR1B/AVP Receptor V3.

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human AVP Receptor V3

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Synonyms

Antidiuretic hormone receptor 1b; Arginine vasopressin receptor 1B; Arginine vasopressin receptor 3; AVPR V1b; AVPR V3; Avpr1b; AVPR3; Pituitary vasopressin receptor 3; V1bR; V1BR_HUMAN; Vasopressin V1b receptor; Vasopressin V3 receptor; VPR3.

Properties

For facs or microscopy Alexa 1 conjugate.Alexa Fluor 488 has the same range to that of fluorescein isothiocyanate (FITC), yet the Anti-AVPR1B/AVP Receptor V3 has a very high photo stability. As a result of this photo stability, it has turned into an antibody for fluorescent microscopy and FACS FLOW cytometry. It is distinguished in the FL1 of a FACS-Calibur or FACScan. Also Alexa Fluor 488 is pH stable.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Description

The receptors are ligand binding factors of type 1, 2 or 3 and protein-molecules that receive chemical-signals from outside a cell. When such chemical-signals couple or bind to a receptor, they cause some form of cellular/tissue-response, e.g. a change in the electrical-activity of a cell. In this sense, am olfactory receptor is a protein-molecule that recognizes and responds to endogenous-chemical signals, chemokinesor cytokines e.g. an acetylcholine-receptor recognizes and responds to its endogenous-ligand, acetylcholine. However, sometimes in pharmacology, the term is also used to include other proteins that are drug-targets, such as enzymes, transporters and ion-channels.

Background of the antigen

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).